AGRX RSI Chart
Last 30 days
2.7%
Last 90 days
-68.3%
Trailing 12 Months
-90.9%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2024 | 21.5M | 0 | 0 | 0 |
2023 | 12.9M | 16.3M | 20.0M | 19.6M |
2022 | 5.7M | 6.7M | 8.4M | 10.9M |
2021 | 1.6M | 2.5M | 3.3M | 4.1M |
2020 | 0 | 0 | 0 | 749.0K |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Oct 03, 2023 | coiante scott m | acquired | - | - | 20,000 | chief financial officer |
Jun 28, 2023 | gilmore geoffrey | acquired | - | - | 20,216 | chief administrative officer |
Jun 28, 2023 | welsh amy | acquired | - | - | 13,500 | chief commercial officer |
Jun 28, 2023 | altomari alfred | acquired | - | - | 46,463 | chief executive officer |
Jun 28, 2023 | conway robert g | acquired | - | - | 13,500 | chief supply chain officer |
Jun 28, 2023 | korner paul | acquired | - | - | 13,500 | chief medical officer |
Jun 08, 2023 | fischer seth h. z. | acquired | - | - | 935 | - |
Jun 08, 2023 | torrente josephine | acquired | - | - | 935 | - |
Jun 08, 2023 | hubbard john w | acquired | - | - | 935 | - |
Jun 08, 2023 | carson sandra | acquired | - | - | 935 | - |
Which funds bought or sold AGRX recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 16, 2024 | COMERICA BANK | sold off | -100 | -8.00 | - | -% |
May 15, 2024 | STATE STREET CORP | sold off | -100 | -21,144 | - | -% |
May 15, 2024 | MORGAN STANLEY | sold off | -100 | -88.00 | - | -% |
May 15, 2024 | INVESTOR AB | unchanged | - | -2,824 | 596 | -% |
May 15, 2024 | ARMISTICE CAPITAL, LLC | sold off | -100 | -210,600 | - | -% |
May 15, 2024 | Tower Research Capital LLC (TRC) | sold off | -100 | -6,388 | - | -% |
May 15, 2024 | Royal Bank of Canada | sold off | -100 | -2,000 | - | -% |
May 15, 2024 | CITADEL ADVISORS LLC | sold off | -100 | -37,532 | - | -% |
May 13, 2024 | UBS Group AG | sold off | -100 | -2,705 | - | -% |
May 13, 2024 | GEODE CAPITAL MANAGEMENT, LLC | sold off | -100 | -26,808 | - | -% |
Unveiling Agile Therapeutics Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Agile Therapeutics Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
JNJ | 372.2B | 85.6B | 9.67 | 4.35 | ||||
MRK | 332.3B | 61.4B | 144.1 | 5.41 | ||||
AMGN | 167.7B | 29.5B | 44.55 | 5.68 | ||||
PFE | 162.3B | 57.8B | 129.52 | 2.81 | ||||
GILD | 84.4B | 27.4B | 174.21 | 3.07 | ||||
TEVA | 18.4B | 16.0B | -37.29 | 1.15 | ||||
MID-CAP | ||||||||
ALKS | 4.1B | 1.7B | 9.41 | 2.37 | ||||
PRGO | 4.1B | 4.6B | -528.11 | 0.89 | ||||
BHC | 2.5B | 9.0B | -5.45 | 0.28 | ||||
AMPH | 2.1B | 676.2M | 13.75 | 3.14 | ||||
SMALL-CAP | ||||||||
TLRY | 1.5B | 743.2M | -4.35 | 2.06 | ||||
TXMD | 25.8M | 1.3M | -3.49 | 19.84 | ||||
ACRX | 18.4M | 89.6M | -1.29 | 0.19 | ||||
AGRX | 2.5M | 21.5M | -0.32 | 0.12 | ||||
ACOR | 633.5K | 115.7M | 0 | 0.01 |
Agile Therapeutics Inc News
Income Statement (Quarterly) | |||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 |
Revenue | 58.1% | 5,716,000 | 3,614,500 | 6,662,000 | 5,503,000 | 3,813,000 | 3,995,500 | 3,002,000 | 2,126,000 | 1,761,000 | 1,513,500 | 1,287,000 | 1,185,000 | 116,000 | 749,000 |
Cost Of Revenue | -23.3% | 1,680,000 | 2,191,000 | 2,477,000 | 2,307,000 | 2,003,000 | 1,653,000 | 1,425,000 | 2,231,000 | 1,527,000 | 5,701,000 | 2,711,000 | 1,145,000 | 1,161,000 | - |
Gross Profit | 183.5% | 4,036,000 | 1,423,500 | 4,185,000 | 3,196,000 | 1,810,000 | 2,342,500 | 1,577,000 | -105,000 | 234,000 | -4,187,500 | -1,424,000 | 40,000 | -1,045,000 | 467,000 |
Operating Expenses | 24.1% | 6,793,000 | 5,474,500 | 8,185,000 | 8,322,000 | 8,518,000 | 9,220,000 | 20,285,000 | 11,293,000 | 15,807,000 | 18,170,500 | 14,350,000 | 16,691,000 | 15,177,000 | 17,208,000 |
S&GA Expenses | -1.3% | 3,682,000 | 3,729,000 | 4,800,000 | 4,570,000 | 4,670,000 | 6,845,500 | 5,560,000 | 7,411,000 | 10,553,000 | 13,004,500 | 9,386,000 | 11,977,000 | 9,253,000 | 10,669,500 |
R&D Expenses | 816.7% | 495,000 | 54,000 | 705,000 | 703,000 | 763,000 | 352,000 | 788,000 | 856,000 | 1,257,000 | 1,673,000 | 1,593,000 | 862,000 | 2,123,000 | 3,012,000 |
EBITDA Margin | 54.3% | -0.30 | -0.66 | -0.61 | -1.02 | -1.31 | -2.36 | -4.79 | -7.59 | -10.97 | -15.87 | -19.09 | -25.49 | -35.27 | - |
Interest Expenses | -39.2% | 185,000 | 304,500 | 341,000 | 372,000 | 402,000 | 432,000 | 1,004,000 | 823,000 | 872,000 | 1,000,000 | 999,000 | 993,000 | 922,000 | 904,000 |
Income Taxes | - | - | - | - | - | - | - | - | - | -4,675,000 | - | - | - | - | - |
Earnings Before Taxes | 128.7% | 1,284,000 | -4,468,500 | -799,000 | -3,809,000 | -5,390,000 | -3,930,000 | -5,930,000 | -5,168,000 | -15,060,000 | -19,530,000 | -16,772,000 | -17,637,000 | -17,128,000 | -17,620,000 |
EBT Margin | 50.9% | -0.36 | -0.74 | -0.70 | -1.17 | -1.58 | -2.76 | -5.44 | -8.45 | -12.01 | -17.33 | -20.72 | -27.45 | -37.91 | - |
Net Income | 128.7% | 1,284,000 | -4,469,000 | -799,000 | -3,809,000 | -5,389,000 | -3,930,000 | -5,930,000 | -5,168,000 | -10,385,000 | -19,530,000 | -16,772,000 | -17,637,000 | -17,128,000 | -17,620,000 |
Net Income Margin | 50.9% | -0.36 | -0.74 | -0.70 | -1.17 | -1.58 | -2.33 | -4.88 | -7.75 | -11.19 | -17.33 | -20.72 | -27.45 | -37.91 | - |
Free Cashflow | -1539.5% | -2,476,000 | 172,000 | 365,000 | -8,519,000 | -1,595,000 | -1,559,000 | -16,703,000 | -2,941,000 | -14,877,000 | -16,673,000 | -18,645,000 | -15,414,000 | -14,739,000 | - |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Assets | 23.0% | 13.00 | 10.00 | 11.00 | 13.00 | 14.00 | 14.00 | 18.00 | 33.00 | 29.00 | 39.00 | 37.00 | 52.00 | 59.00 | 73.00 | 89.00 | 103 | 109 | 50.00 | 34.00 | 25.00 | 26.00 |
Current Assets | 25.8% | 12.00 | 10.00 | 10.00 | 12.00 | 11.00 | 11.00 | 15.00 | 18.00 | 14.00 | 24.00 | 22.00 | 37.00 | 44.00 | 57.00 | 73.00 | 89.00 | 95.00 | 35.00 | 20.00 | 11.00 | 12.00 |
Cash Equivalents | 2.3% | 3.00 | 3.00 | 3.00 | 3.00 | 4.00 | 5.00 | 6.00 | 13.00 | 4.00 | 19.00 | 15.00 | 26.00 | 16.00 | 14.00 | 24.00 | 39.00 | 94.00 | 34.00 | 18.00 | 11.00 | 12.00 |
Inventory | 36.9% | 4.00 | 3.00 | 2.00 | 3.00 | 2.00 | 1.00 | 2.00 | 2.00 | 3.00 | 1.00 | 3.00 | 3.00 | 2.00 | - | - | - | - | - | - | - | - |
Net PPE | -33.3% | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 12.00 | 12.00 | 12.00 | 13.00 | 13.00 | 14.00 | 14.00 | 14.00 | 14.00 | 14.00 | 14.00 | 14.00 | 14.00 | 14.00 |
Liabilities | -13.7% | 23.00 | 27.00 | 23.00 | 25.00 | 23.00 | 20.00 | 21.00 | 30.00 | 35.00 | 35.00 | 26.00 | 28.00 | 24.00 | 24.00 | 23.00 | 22.00 | 18.00 | 4.00 | 3.00 | 3.00 | 3.00 |
Current Liabilities | 3.2% | 21.00 | 21.00 | 18.00 | 15.00 | 19.00 | 13.00 | 12.00 | 29.00 | 26.00 | 29.00 | 10.00 | 12.00 | 9.00 | 7.00 | 7.00 | 6.00 | 3.00 | 4.00 | 2.00 | 2.00 | 1.00 |
Long Term Debt | -100.0% | - | 2.00 | - | - | - | 1.00 | - | - | - | - | 16.00 | 16.00 | 16.00 | 16.00 | 16.00 | 16.00 | 15.00 | - | - | - | - |
LT Debt, Current | -100.0% | - | 2.00 | 2.00 | 2.00 | 2.00 | 1.00 | 1.00 | 13.00 | 12.00 | 17.00 | - | - | - | - | - | - | - | - | - | - | - |
Shareholder's Equity | 36.7% | -10.32 | -16.32 | - | - | -9.43 | -5.54 | 6.00 | 2.00 | 3.00 | 4.00 | 11.00 | 25.00 | 35.00 | 49.00 | 66.00 | 81.00 | 91.00 | 46.00 | 0.00 | 273 | 271 |
Retained Earnings | 0.3% | -421 | -423 | -418 | -417 | -414 | -408 | -404 | -398 | -393 | -383 | -363 | -346 | -329 | -312 | -295 | -279 | -268 | -260 | -254 | -249 | -246 |
Additional Paid-In Capital | 1.2% | 412 | 407 | 406 | 406 | 405 | 403 | 402 | 401 | 388 | 387 | 374 | 372 | 364 | 362 | 361 | 360 | 359 | 306 | 286 | 273 | 271 |
Accumulated Depreciation | -100.0% | - | 0.00 | - | - | - | 0.00 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Shares Outstanding | 131.3% | 7.00 | 3.00 | 2.00 | 2.00 | 47.00 | 1.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - | - | - | - | - | - | - | - | - |
Float | - | - | - | - | 5.00 | - | - | - | 14.00 | - | - | - | 101 | - | - | - | 197 | - | - | - | 52.00 | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Cashflow From Operations | -1539.5% | -2,476 | 172 | 365 | -8,519 | -1,595 | -1,559 | -16,703 | -2,934 | -14,751 | -16,618 | -18,580 | -15,336 | -14,668 | -17,342 | -15,320 | -6,765 | -7,884 | -3,270 | -5,080 | -2,378 | -4,961 |
Share Based Compensation | -40.9% | 333 | 563 | 439 | 481 | 498 | 524 | 536 | 669 | 764 | 866 | 887 | 843 | 742 | 711 | 647 | 839 | 621 | 415 | 378 | 479 | 490 |
Cashflow From Investing | - | - | - | - | - | - | - | - | -7.00 | -126 | -55.00 | 4,935 | 18,395 | 16,185 | 7,527 | -173 | -47,880 | -164 | -68.00 | - | - | - |
Cashflow From Financing | 620.5% | 2,535 | -487 | -278 | 6,875 | 778 | 660 | 9,821 | 12,225 | -523 | 21,081 | 2,262 | 6,595 | 484 | 115 | 210 | 166 | 67,494 | 19,447 | 12,894 | 1,404 | 8,670 |
Statements of Operations and Comprehensive Income (Loss) - USD ($) $ in Thousands | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
Statements of Operations and Comprehensive Income (Loss) | ||
Revenues, net | $ 5,716 | $ 3,813 |
Cost of product revenues | 1,680 | 2,003 |
Gross profit | 4,036 | 1,810 |
Operating expenses: | ||
Research and development | 495 | 763 |
Selling and marketing | 3,682 | 4,670 |
General and administrative | 2,616 | 3,085 |
Total operating expenses | 6,793 | 8,518 |
Loss from operations | (2,757) | (6,708) |
Other income (expense) | ||
Interest income | 23 | 33 |
Interest expense | (185) | (402) |
Unrealized gain on warrant liability | 4,203 | 1,687 |
Total other income (expense), net | 4,041 | 1,318 |
Income (loss) before benefit from income taxes | 1,284 | (5,390) |
Net income (loss) and comprehensive income (loss) | $ 1,284 | $ (5,390) |
Net income (loss) per share (basic) (in dollars per share) | $ 0.28 | $ (5.91) |
Net income (loss) per share (diluted) (in dollars per share) | $ 0.28 | $ (5.91) |
Weighted-average common shares (basic) (in shares) | 4,631,902 | 912,044 |
Weighted-average common shares (diluted) (in shares) | 4,631,902 | 912,044 |
Balance Sheets - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 2,615 | $ 2,557 |
Accounts receivable, net | 4,813 | 3,392 |
Inventory, net | 3,748 | 2,738 |
Prepaid expenses and other current assets | 811 | 843 |
Total current assets | 11,987 | 9,530 |
Property and equipment, net | 50 | 75 |
Right of use asset | 335 | 412 |
Other non-current assets | 238 | 238 |
Total assets | 12,610 | 10,255 |
Current liabilities: | ||
Long-term debt, current portion | 1,515 | |
Notes payable, current portion | 191 | |
Accounts payable | 12,620 | 9,574 |
Accrued expenses | 8,443 | 9,131 |
Lease liability, current portion | 378 | 366 |
Total current liabilities | 21,441 | 20,777 |
Lease liabilities, long-term | 100 | |
Warrant liability | 1,493 | 5,696 |
Total liabilities | 22,934 | 26,573 |
Commitments and contingencies (Note 9) | ||
Stockholders' deficit | ||
Preferred stock, $0.0001 par value, 10,000,000 shares authorized, 4,850 issued and no shares outstanding at March 31, 2024 and no shares issued and outstanding at December 31, 2023 | ||
Common stock, $0.0001 par value, 300,000,000 shares authorized, 6,856,229 and 2,963,657 issued and outstanding at March 31, 2024 and December 31, 2023, respectively | 5 | 4 |
Additional paid-in capital | 411,555 | 406,846 |
Accumulated deficit | (421,884) | (423,168) |
Total stockholders' deficit | (10,324) | (16,318) |
Total liabilities and stockholders' deficit | $ 12,610 | $ 10,255 |
 | Mr. Alfred F. Altomari |
---|---|
 | agiletherapeutics.com |
 | Pharmaceuticals |
 | 22 |